J.P. Morgan: Maintains "Overweight" rating on Z.AI (02513), target price HK$1,200
Management noted that GLM-5.3-Flash inference on domestic chips has achieved positive gross margin, demonstrating its leading advantage in localized hardware integration.
J.P. Morgan noted in a research report that Z.AI (02513) continues to make steady progress in the generative AI field. Although market sentiment toward the stock has weakened, the company's fundamentals remain solid, commercialization progress is in line with expectations, and China's AI applications are still at an early stage. Taking all this into account, the bank believes the market is currently overly pessimistic about the company's performance and maintains its "Overweight" rating on Z.AI with a target price of HK$1,200.
The report mentioned that commercialization of Z.AI's main GLM series models is progressing smoothly, cooperation with major domestic and international cloud service providers continues to advance, revenue-sharing performance is satisfactory, and profit margins are improving quarter by quarter. Management reiterated its target of US$3 billion in annualized recurring revenue by the end of 2026. In addition, Z.AI has already been using a cluster of more than 100,000 domestic chips for large-scale low-cost inference, and management further noted that inference of GLM-5.3-Flash on domestic chips has achieved positive gross margins, demonstrating its leading advantage in localized hardware integration.
Regarding the U.S. Department of Commerce's Bureau of Industry and Security (BIS) earlier issuing an interim final rule aimed at prohibiting companies in China and other countries from remotely accessing advanced U.S. chips through third-country data centers, management believes the new rule has limited impact on the company, given that its computing power is concentrated domestically and its overseas business uses computing assets held by partners.
On financial condition, management said the company is well funded and explicitly ruled out any equity or convertible bond financing before a planned A-share listing. The company has completed two large fundraisings this year, raising HK$31.4 billion through a placement in July and about US$5 billion in September, including a US$2 billion placement and US$3 billion in zero-coupon convertible bonds, providing ample ammunition for future R&D and expansion.
J.P. Morgan noted that more than 80% of Z.AI's revenue currently comes from the Chinese market, so the pace of adoption of domestic AI applications in China is a key driver of the group's growth. Risk factors include export controls and geopolitical risks, intensifying competition, execution and profitability pressure from continued high R&D investment, uncertainty over customer adoption, and reliance on computing infrastructure and external suppliers.
Related Articles

CMBI: Raises SBP GROUP (01177) Target Price to HK$9, Maintains "Buy" Rating

Citi's Top Data Center Pick Is Equinix (EQIX.US): AI Access Points Catch Up to Seven Years of Cloud in One Year, Interconnection Networks Emerge as the Biggest Winner
BofA Securities: Maintains JD HEALTH (06618) Target Price at HK$57 and "Buy" Rating
CMBI: Raises SBP GROUP (01177) Target Price to HK$9, Maintains "Buy" Rating

Citi's Top Data Center Pick Is Equinix (EQIX.US): AI Access Points Catch Up to Seven Years of Cloud in One Year, Interconnection Networks Emerge as the Biggest Winner

BofA Securities: Maintains JD HEALTH (06618) Target Price at HK$57 and "Buy" Rating





